



“Role of Repetitive Transcranial Magnetic Stimulation on Drug Resistant Focal Epilepsy”

Thesis

Submitted for *Partial* Fulfillment of M.D.
Degree in Neurology

By

Ahmed Kamal Ahmed Hassan

M.B.B.Ch - Cairo University

Master of Neuropsychiatry- Ain Shams University

Supervisors

Prof. Samia Ashour Mohamed Helal

Professor of Neuropsychiatry

Faculty of Medicine - Ain Shams University

Prof. Ahmed Abd Elmonem Gaber

Professor of Neuropsychiatry

Faculty of Medicine - Ain Shams University

Assist. Prof. Tamer Hussien Fahmy

Assistant Professor of Neuropsychiatry

Faculty of Medicine - Ain Shams University

*Faculty of Medicine
Ain Shams University*

2019



ACKNOWLEDGEMENT

First of all, thanks to **Allah** whose magnificent help was the main factor in completing this work.

No words could express my deepest thanks and appreciation to

Prof. Samia Ashour Mohamed Helal

Prof. Ahmed Abd Elmonem Gaber

Prof. Asses Dr. Tamer Hussien Fahmy

Dr. Sherif Elwan and

Dr. Heba Hamed

For inspiring me with the idea of this work. Their patience, precious advice and guidance enlightened my way throughout this work.

I want also to express my profound gratitude to continuous help in completing this work.

Kasr Al Ainy Epilepsy unit

Ain Shams Epilepsy unit

Ain Shams Neuromodulation unit

Finally, my deepest thanks to all my family and colleagues who helped me in the production of this work.

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ □

لَا يُكَلِّفُ اللَّهُ نَفْسًا إِلَّا وُسْعَهَا لَهَا مَا كَسَبَتْ
وَعَلَيْهَا مَا اكْتَسَبَتْ رَبَّنَا لَا تُؤَاخِذْنَا إِنْ نَسِينَا أَوْ
أَخْطَأْنَا رَبَّنَا وَلَا تَحْمِلْ عَلَيْنَا إصْرًا كَمَا حَمَلْتَهُ
عَلَى الَّذِينَ مِنْ قَبْلِنَا رَبَّنَا وَلَا تُحَمِّلْنَا مَا لَا طَاقَةَ
لَنَا بِهِ وَاعْفُ عَنَّا وَاعْفِرْ لَنَا وَارْحَمْنَا أَنْتَ مَوْلَانَا
فَانصُرْنَا عَلَى الْقَوْمِ الْكَافِرِينَ

صدق الله العظيم

سورة البقرة (٢٨٦)

Contents

Subjects	Page
List of abbreviations.....	II
List of figures.....	IV
List of tables.....	VI
• Introduction	1
• Aim of the Work	4
• Review of Literature	
♦ Chapter (1): Classification of Epileptic Seizures	5
♦ Chapter (2): Pathophysiology of Epilepsy	18
♦ Chapter (3): Seizure Semiology	34
♦ Chapter (4): TMS in Epilepsy	61
• Subjects and Methods	65
• Results	74
• Discussion	92
• Conclusion	99
• Recommendations	100
• Summary	101
• References	103
• Appendix	122
• Arabic Summary	

List of Abbreviations

ABC	: ATP-binding cassette
AEDs	: Antiepileptic drugs
BBB	: Blood–brain barrier
EEG	: Electroencephalogram
FLE	: Frontal lobe epilepsy
GABA	: Gamma-aminobutyric acid
GABAB	: γ -aminobutyric acid type B
HS	: Hippocampal sclerosis
IEDs	: Interictal epileptiform discharges
ILAE	: International league against epilepsy
LTD	: Long-term depression
LTP	: Long-term potentiation
MCD	: Malformations of cortical development
MEP	: Motor-evoked potential
MTS	: Mesial temporal sclerosis
NMDA	: N-methyl-d-aspartate
OLE	: Occipital lobe epilepsy
PDS	: Paroxysmal depolarization shift
PLE	: Parietal lobe epilepsy

List of Abbreviations

rTMS	: Repetitive transcranial magnetic stimulation
SMA	: Supplementary motor area
SMA	: Supplementary motor area
TLE	: Temporal lobe epilepsy
TMS	: Transcranial magnetic stimulation
WHO	: World Health Organization

List of Figures

<u>No.</u>	<u>Figure</u>	<u>Page</u>
<u>1</u>	The ILAE 2017 operational classification of seizure.	16
<u>2</u>	Framework for classification of the epilepsies.	17
<u>3</u>	Summary of pathophysiology of epilepsy	20
<u>4</u>	Proposed cascade of events following a seizure leading to potential adverse sequelae (medically resistant status epilepticus, epileptogenesis, learning impairment)	23
<u>5</u>	Ligand-gated and voltage-gated channels largely involved in the paroxysmal depolarization shift (PDS) generation.	25
<u>6</u>	Hypothesized Biologic Mechanisms of Drug Resistance in Epilepsy. At locations labeled 1 is overexpression of efflux transporters in capillary endothelial cells that constitute the blood–brain barrier.	30
<u>7</u>	Fate of patients that were conducted for rTMS treatment.	66
<u>8</u>	The 10-20 International system of EEG electrode placement.	70
<u>9</u>	The 10-10 International system of EEG electrode placement Blue circles represent the location of 10-20 EEG electrodes.	71

List of Figures

<u>No.</u>	<u>Figure</u>	<u>Page</u>
<u>10</u>	10-10 electrode placement and the nearest broadman area center.	71
<u>11</u>	Seizure Semiology among 30 epilepsy patients.	79
<u>12</u>	Comparison between the 2 groups as regards seizure % reduction rate.	85

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>1</u>	International League Against Epilepsy classification of epileptic seizures.	6
<u>2</u>	ILAE classification of epilepsies and epileptic syndromes.	8
<u>3</u>	ILAE classification of epileptic syndromes.	9
<u>4</u>	International League Against Epilepsy classification of epileptic seizures.	11
<u>5</u>	Seizure history taking and its significance.	34
<u>6</u>	Semiological Features of TLE - lateralizing or localizing Value.	45
<u>7</u>	Semiological features differentiating MTLE and LTLE.	48
<u>8</u>	Semiology of frontal versus temporal lobe seizures.	49
<u>9</u>	Comparison between patients with their clinical semiological diagnosis MRI and EEG findings, site of rTMS and correlation ratio stimulation.	74
<u>10</u>	Socio-demographic, clinical, MRI, EEG and intervention data among 30 epilepsy patients.	77
<u>11</u>	Baseline seizure diary assessment among 30 epilepsy patients.	80

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>12</u>	Follow up (1-month) seizure diary assessment among 30 epilepsy patients.	81
<u>13</u>	Comparison between the 2 groups as regards socio-demographic and clinical data radiological data using Chi square tests.	82
<u>14</u>	Comparison between the 2 groups as regards radiological data using Chi square test.	84
<u>15</u>	Comparison between the 2 groups as regards baseline seizure diary assessment using Mann-Whitney's U tests.	83
<u>16</u>	Comparison between active TMS patients and sham TMS patients as regards serial seizure diary assessments using Wilcoxon's test.	83
<u>17</u>	Comparison between the 2 groups as regards% Reduction rate using Mann-Whitney's U tests.	84
<u>18</u>	Comparison between the 2 groups as regards 50% Reduction rate (of seizure frequency) using Chi square tests.	85

Introduction

Epilepsy is a chronic disorder of the brain that affects people of all ages, approximately 50 million people live with epilepsy worldwide (**WHO, 2018**). It is the commonest neurological condition, with a prevalence of 0.5–1%. It can occur at any age, but is particularly likely to develop in the very young and the elderly (**Hart, 2012**).

Epilepsy exists when someone has an epileptic seizure and their brain “demonstrates a pathologic and enduring tendency to have recurrent seizures”. epilepsy is diagnosed when an individual has at least two unprovoked or reflex seizures >24 h apart, one unprovoked (or reflex) seizure and a probability of having another seizure similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years, and or diagnosis of an epilepsy syndrome. While an epileptic seizure is defined conceptually as: “a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain (**Fisher et al., 2014**). Evidence that increases the probability of having additional seizures includes epileptiform activity on electroencephalogram (EEG) or a potential abnormality on brain imaging (**Jessica et al., 2017**).

The previous definition considered the diagnosis of epilepsy only after two unprovoked seizures occurring at least 24 hours apart and was based on data demonstrating that the cumulative risk for a relapse after a first unprovoked seizure is about 40%, whereas the risk for further unprovoked seizures approaches 80% in those who have experienced at least two unprovoked seizures (**Beretta et al., 2017**).

Focal seizures also called partial, topographical, anatomical and localized related seizures initially generate in and affect just one part of the brain or a whole hemisphere. Symptoms vary according to where the seizure occurs particularly at onset, are determined by localization and not etiology. However, specific anatomical localization is sometimes difficult, as when seizures originate from clinically silent epileptogenic regions (**Bradley and Daroff, 2012**).

Drug-resistant epilepsy is defined as failure of adequate trials of two tolerated, appropriately chosen and administered antiepileptic drugs (whether as monotherapy or in combination) to achieve sustained seizure freedom. And, about 20 to 40 percent of patients with epilepsy are refractory to medications (**Kwan et al., 2010**). This condition is also referred to as intractable, medically refractory, or pharmaco-resistant epilepsy (**Kwan et al., 2011**).

A core feature of drug-resistant epilepsy (DRE) is hyperexcitability of the cortical areas (**Tassinari et al., 2003**). These syndromes may benefit from repeated transcranial magnetic stimulation (rTMS) (**Theodore, 2003**).

The Frequency and severity of seizures vary among individuals with DRE and are important considerations when weighing treatment options. They have an impact in the context of the individual's life, job, and other psychosocial circumstances (**Benbadis et al., 2000**).

Neurostimulation based treatments for epilepsy is an alternative for the many patients who remain refractory to standard antiepileptic drugs (AEDs) (**Fisher, 2012**).

The potential therapeutic effect of rTMS on focal epilepsy, however, has been much less clear. Controlled clinical trials of low-frequency rTMS in drug resistant epilepsy patients had yielded disparate outcomes, with seizures and interictal epileptiform discharges (IEDs) reduced in some studies but not in others. Differences in subject selection, location of rTMS target, and stimulation parameters could all potentially have played a role in the variability of outcomes (**Cantello et al., 2007**).

Aim of the Study

To assess the effectiveness of rTMS as adjunctive treatment in patients with drug resistant focal epilepsy.

Chapter (1)

Classification of Epileptic Seizures

The international league against epilepsy (ILAE) Commission 1989 classified focal epilepsies, according to their topographical/anatomical origin as: frontal lobe epilepsies, temporal lobe epilepsies, parietal lobe epilepsies and occipital lobe epilepsies. These epilepsies may be idiopathic, cryptogenic or symptomatic. The ILAE diagnostic scheme further classified focal epilepsies according to whether they were limbic or neocortical (**Engel, 2006**). Simple and complex focal seizures may account for 60–70% of all epilepsies, and almost half originate from temporal lobe structures (**Banerjee and Hauser, 2008**). There are numerous causes of symptomatic and cryptogenic focal epilepsies, such as: benign or malignant tumours, viral and other infectious and parasitic diseases, cerebrovascular disorders, malformations of cortical development, genetically determined brain and metabolic disorders and, or trauma and other injuries (**Sisodiya, 2004**).